Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
CLPT 
Clearpoint Neuro Inc (CLPT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/13/2025: CLPT (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $29
1 Year Target Price $29
| 2 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -52.93% | Avg. Invested days 24 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/13/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 297.91M USD | Price to earnings Ratio - | 1Y Target Price 29 |
Price to earnings Ratio - | 1Y Target Price 29 | ||
Volume (30-day avg) 2 | Beta 0.85 | 52 Weeks Range 9.46 - 19.22 | Updated Date 08/13/2025 |
52 Weeks Range 9.46 - 19.22 | Updated Date 08/13/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.76 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-08-12 | When - | Estimate -0.1967 | Actual -0.21 |
Profitability
Profit Margin -64.51% | Operating Margin (TTM) -72.63% |
Management Effectiveness
Return on Assets (TTM) -32.39% | Return on Equity (TTM) -76.21% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 290660021 | Price to Sales(TTM) 9.24 |
Enterprise Value 290660021 | Price to Sales(TTM) 9.24 | ||
Enterprise Value to Revenue 9.03 | Enterprise Value to EBITDA -7.07 | Shares Outstanding 28265000 | Shares Floating 25560012 |
Shares Outstanding 28265000 | Shares Floating 25560012 | ||
Percent Insiders 8.24 | Percent Institutions 37.14 |
Upturn AI SWOT
Clearpoint Neuro Inc
Company Overview
History and Background
Clearpoint Neuro Inc., formerly MRI Interventions, Inc., was founded in 1998. It focuses on developing and commercializing innovative platforms for performing minimally invasive surgical procedures in the brain and heart. Significant milestones include FDA clearances for its ClearPoint System and initial commercialization of its neuro-intervention platform. They have evolved to focus more on biologics and drug delivery into the brain.
Core Business Areas
- Neuro Navigation: Provides the ClearPoint System, a platform for delivering therapies and performing minimally invasive procedures in the brain. This segment is focused on enabling access to the brain with precision and real-time MRI guidance.
- Drug Delivery: Focuses on delivering drugs and biologics directly into the brain, including gene therapy and cell therapy applications. They are working with pharma partners.
Leadership and Structure
Joe Burnett is the President and CEO. The company has a Board of Directors overseeing strategic direction and corporate governance.
Top Products and Market Share
Key Offerings
- ClearPoint System: A neuro-navigation platform used for minimally invasive brain procedures, including laser ablation, biopsies, and gene therapy delivery. Market share is estimated around 40% within the MRI-guided neuro-intervention market. Main competitors include Medtronic and Monteris Medical.
- SmartFlow Cannula: A device used to deliver drugs and biologics directly into the brain. Specific market share data is not publicly available but is growing with the rise of gene and cell therapies for neurological disorders. Competitors include those offering convection-enhanced delivery (CED) systems.
Market Dynamics
Industry Overview
The neuro-intervention market is growing, driven by the increasing prevalence of neurological disorders, advancements in minimally invasive surgical techniques, and the development of novel therapies for brain diseases.
Positioning
Clearpoint Neuro is positioned as a leader in MRI-guided neuro-intervention, offering a unique platform for precise drug delivery and minimally invasive procedures. Its competitive advantage lies in its real-time MRI guidance capabilities and partnerships with pharmaceutical companies.
Total Addressable Market (TAM)
The TAM for neuro-intervention is estimated to be several billion USD, encompassing both neurosurgical navigation and drug delivery. Clearpoint Neuro is positioned to capture a growing share of this market as the demand for minimally invasive brain procedures and targeted therapies increases.
Upturn SWOT Analysis
Strengths
- Proprietary ClearPoint System with real-time MRI guidance
- Strong relationships with leading pharmaceutical companies for drug delivery
- Minimally invasive technology reduces patient trauma and recovery time
- FDA-cleared platform with proven clinical utility
Weaknesses
- Limited revenue compared to larger medical device companies
- Reliance on partnerships for drug delivery revenue
- High operating expenses related to R&D and commercialization
- Market adoption dependent on physician training and acceptance
Opportunities
- Expanding applications of ClearPoint System in gene therapy and cell therapy
- Increasing demand for minimally invasive neurosurgical procedures
- Growing prevalence of neurological disorders creates a larger patient pool
- Potential for strategic acquisitions to expand product portfolio
Threats
- Competition from larger medical device companies with greater resources
- Regulatory hurdles for new therapies and delivery systems
- Technological advancements by competitors could render ClearPoint System obsolete
- Reimbursement challenges for novel neuro-intervention procedures
Competitors and Market Share
Key Competitors
- MDT
- MRON
- BWAY
Competitive Landscape
Clearpoint Neuro benefits from unique MRI guided procedures. It however, must be weary of Medtronic which is a much larger organization with more capital to spend.
Major Acquisitions
Skylar Medical
- Year: 2024
- Acquisition Price (USD millions): 12
- Strategic Rationale: This acquisition expanded Clearpoint Neuro's portfolio to offer single-use access kits.
Growth Trajectory and Initiatives
Historical Growth: Clearpoint Neuro has experienced revenue growth driven by increased adoption of the ClearPoint System and growth in drug delivery partnerships.
Future Projections: Analysts project continued revenue growth for Clearpoint Neuro driven by expanding applications in gene therapy and cell therapy, as well as increasing demand for minimally invasive neurosurgical procedures.
Recent Initiatives: Recent strategic initiatives include expanding partnerships with pharmaceutical companies, developing new applications for the ClearPoint System, and investing in R&D to enhance its technology platform.
Summary
Clearpoint Neuro is a growing company in the neuro-intervention space, possessing a unique platform in MRI-guided procedures. Partnerships with pharmaceutical companies are driving growth in drug delivery. They are still operating at a loss and need to monitor their expenses. Competition from larger players like Medtronic is a constant threat, and continued innovation is crucial for maintaining its competitive edge.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Investor Presentations
- Analyst Reports
- Company Website
- Market Research Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor. Market share data is based on estimates and may not be precise. Financial numbers are example data and need to be updated with current actual values.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Clearpoint Neuro Inc
Exchange NASDAQ | Headquaters Solana Beach, CA, United States | ||
IPO Launch date 2020-02-12 | President, CEO & Director Mr. Joseph Michael Burnett | ||
Sector Healthcare | Industry Medical Devices | Full time employees 115 | Website https://www.clearpointneuro.com |
Full time employees 115 | Website https://www.clearpointneuro.com | ||
ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain. It has license and collaboration agreement with Clinical Laserthermia Systems AB; license and research agreement with Koninklijke Philips N.V.; UCB Biopharma SRL; NE Scientific, LLC; and University of California, San Francisco, and Johns Hopkins University. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.